Elizabeth R Kessler, Elizabeth Wulff-Burchfield, Jennifer Phillips, Wesley Peters, Tracy McGowan, Pankaj Aggarwal
{"title":"Elevating the Patient Voice: Understanding Treatment Preferences in Patients with Advanced Prostate Cancer.","authors":"Elizabeth R Kessler, Elizabeth Wulff-Burchfield, Jennifer Phillips, Wesley Peters, Tracy McGowan, Pankaj Aggarwal","doi":"10.1007/s12325-025-03214-7","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>With multiple oral medications currently available for patients with prostate cancer, there is a need to understand how patients' preferences and experiences are impacted by several factors including pill burden and dosing frequency. This study aimed to understand medication preferences from patients with advanced prostate cancer (APC).</p><p><strong>Methods: </strong>We conducted a cross-sectional, online survey of patients with APC living in the USA.</p><p><strong>Results: </strong>The survey was completed by 100 patients with a median age of 65 years (range 35-79). Most patients were White (53%) with 31% Black and 15% Hispanic. Nearly half (48%) reported taking more than five pills per day and 50% reported taking more than three prescription medications per day. Nearly two-thirds (63%) reported difficulty remembering to take pills multiple times per day and 91% said they would choose a one-pill-once-daily option over a multi-pill regimen. Twenty-two (22%) patients had difficulty swallowing pills or were unsure. Of these 22, 21 (95%) considered it important that a pill can be dispersed in water or applesauce. Most patients (81%) had undergone chemotherapy previously and 80% reported taking oral medications for prostate cancer. Eighty-nine (89%) patients said they would prefer an oral treatment option compared to intravenous chemotherapy.</p><p><strong>Conclusion: </strong>Most patients prefer a one-pill-once-daily regimen. Most patients prefer the option of an oral treatment regimen over intravenous chemotherapy. When discussing treatment options, providers should consider the individual patient's preferences and engage in shared decision-making.</p>","PeriodicalId":7482,"journal":{"name":"Advances in Therapy","volume":" ","pages":""},"PeriodicalIF":3.4000,"publicationDate":"2025-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Advances in Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12325-025-03214-7","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
Abstract
Introduction: With multiple oral medications currently available for patients with prostate cancer, there is a need to understand how patients' preferences and experiences are impacted by several factors including pill burden and dosing frequency. This study aimed to understand medication preferences from patients with advanced prostate cancer (APC).
Methods: We conducted a cross-sectional, online survey of patients with APC living in the USA.
Results: The survey was completed by 100 patients with a median age of 65 years (range 35-79). Most patients were White (53%) with 31% Black and 15% Hispanic. Nearly half (48%) reported taking more than five pills per day and 50% reported taking more than three prescription medications per day. Nearly two-thirds (63%) reported difficulty remembering to take pills multiple times per day and 91% said they would choose a one-pill-once-daily option over a multi-pill regimen. Twenty-two (22%) patients had difficulty swallowing pills or were unsure. Of these 22, 21 (95%) considered it important that a pill can be dispersed in water or applesauce. Most patients (81%) had undergone chemotherapy previously and 80% reported taking oral medications for prostate cancer. Eighty-nine (89%) patients said they would prefer an oral treatment option compared to intravenous chemotherapy.
Conclusion: Most patients prefer a one-pill-once-daily regimen. Most patients prefer the option of an oral treatment regimen over intravenous chemotherapy. When discussing treatment options, providers should consider the individual patient's preferences and engage in shared decision-making.
期刊介绍：
Advances in Therapy is an international, peer reviewed, rapid-publication (peer review in 2 weeks, published 3–4 weeks from acceptance) journal dedicated to the publication of high-quality clinical (all phases), observational, real-world, and health outcomes research around the discovery, development, and use of therapeutics and interventions (including devices) across all therapeutic areas. Studies relating to diagnostics and diagnosis, pharmacoeconomics, public health, epidemiology, quality of life, and patient care, management, and education are also encouraged.
The journal is of interest to a broad audience of healthcare professionals and publishes original research, reviews, communications and letters. The journal is read by a global audience and receives submissions from all over the world. Advances in Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of all scientifically and ethically sound research.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
